43 related articles for article (PubMed ID: 36932910)
1. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
3. Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients.
Sabirova Z; Mahnoor S; Lasfar D; Gagné V; Théorêt Y; Leclerc JM; Laverdière C; Sinnett D; Tran TH; Krajinovic M
Pharmacogenet Genomics; 2024 Jul; 34(5):170-173. PubMed ID: 38682355
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
5. Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.
Milosevic G; Kotur N; Krstovski N; Lazic J; Zukic B; Stankovic B; Janic D; Katsila T; Patrinos GP; Pavlovic S; Dokmanovic L
J Med Biochem; 2018 Jul; 37(3):320-327. PubMed ID: 30598629
[TBL] [Abstract][Full Text] [Related]
6. Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial.
Zhou Y; Wang L; Sun LR; Zhang L; Wang HM; Liu XT; Yang F; Wu KL; Liang YL; Zhao BB; Zhuang Y; Fu JQ; Song C; Li Y; Wang LZ; Xu HJ; Gu Y; van den Anker J; Ju XL; Zhu XF; Zhao W
Clin Pharmacol Ther; 2024 Feb; 115(2):213-220. PubMed ID: 37753808
[TBL] [Abstract][Full Text] [Related]
7. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy.
Barone T; Dandekar S; McKeone D; Mulieri K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
[TBL] [Abstract][Full Text] [Related]
8. 6-Mercaptopurine-Associated Sinusoidal Obstructive Syndrome During Interim Maintenance I: A Case Report.
Voelz K; Miller G; Lee-Miller C
J Pediatr Hematol Oncol; 2024 May; ():. PubMed ID: 38775421
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.
Ogungbenro K; Aarons L;
Br J Clin Pharmacol; 2015 Jul; 80(1):86-100. PubMed ID: 25614061
[TBL] [Abstract][Full Text] [Related]
10. Population-Specific Distribution of
Gallardo-Cóndor J; Naranjo P; Atarihuana S; Coello D; Guevara-Ramírez P; Flores-Espinoza R; Burgos G; López-Cortés A; Cabrera-Andrade A
Ther Clin Risk Manag; 2023; 19():1005-1018. PubMed ID: 38050617
[TBL] [Abstract][Full Text] [Related]
11. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
McLeod HL; Krynetski EY; Relling MV; Evans WE
Leukemia; 2000 Apr; 14(4):567-72. PubMed ID: 10764140
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Schwarz UI; Woldanski-Travaglini M; Swanston V; Mikhail M; Cacciotti C; Cairney E; Patel S; Seelisch J; Tole S; Wilejto M; Tirona RG; Kim RB; Zorzi AP
Clin Pharmacol Ther; 2023 Jun; 113(6):1326-1336. PubMed ID: 36932910
[TBL] [Abstract][Full Text] [Related]
16. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
